Article
Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis.
Arthritis and rheumatism - 1 Jul 2003
Mugnier Benedicte, Balandraud Nathalie, Darque Albert, Roudier Chantal, Roudier Jean, Reviron Denis
Abstract excerpt
OBJECTIVE: To test whether the G-to-A polymorphism at position -308 in the promoter of the tumor necrosis factor alpha (TNFalpha) gene influences response to infliximab therapy in patients with rheumatoid arthritis (RA). METHODS: We genotyped 59 RA patients by polymerase chain reaction and subdivided them into two groups: those with the A/A or A/G genotype and those with the G/G genotype. We compared the groups'...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.